TREATMENT OF PATIENTS WITH MODERATE AND SEVERE PSORIASIS - COST-OF-ILLNESS IN THE CZECH REPUBLIC

被引：2
|
作者：
Petrikova, A. [1 ]
Klimes, J. [2 ]
Dolezal, T. [3 ]
Marinov, L.
Petrova, G. [4 ]
机构：
[1] VFU Brno, Brno, Czech Republic
[2] Charles Univ Prague, Fac Pharm, CS-50165 Hradec Kralove, Czech Republic
[3] Inst Hlth Econ & Technol Assessment, Prague, Czech Republic
[4] Med Univ, Fac Pharm, Sofia, Bulgaria
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.406
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A305 / A306
页数：2
相关论文
共 50 条
  • [31] Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
    Kojanova, Martina
    Turkova, Barbora
    Gkalpakiotis, Spyridon
    Cetkovska, Petra
    Fialova, Jorga
    Dolezal, Tomas
    Machovcova, Alena
    Apol, Eydna Didriksen
    ADVANCES IN THERAPY, 2024, 41 (10) : 3951 - 3971
  • [32] The Financial Burden of Acute Nasopharynx and Acute Bronchitis of Children from Different Perspectives: The Cost-Of-Illness Study in the Czech Republic
    Tothova, Dominika
    Soukopova, Jana
    SCIENTIFIC PAPERS OF THE UNIVERSITY OF PARDUBICE-SERIES D-FACULTY OF ECONOMICS AND ADMINISTRATION, 2021, 29 (03):
  • [33] EFFICIENCY (COST/EFFICACY) OF BIOLOGIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS
    Lazaro, P.
    Blasco, A. J.
    Ferrandiz, C.
    Garcia, A.
    Liso, J.
    VALUE IN HEALTH, 2010, 13 (03) : A147 - A147
  • [34] Cost-utility analysis of Amevive™ (alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 331 - 331
  • [35] A nnual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
    Fragoulakis, Vassilis
    Raptis, Efklidis
    Vitsou, Elli
    Maniadakis, Nikolaos
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2015, 7 : 73 - 83
  • [36] Cost-effectiveness analysis of amevivetm (Alefacept) in the treatment of patients with moderate-to-severe psoriasis
    Iskedjian, M
    Barkovsky, L
    Desjardins, O
    Walker, JH
    Dorkalam, M
    Shear, N
    Einarson, TR
    VALUE IN HEALTH, 2005, 8 (03) : 330 - 330
  • [37] COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN TURKEY
    Tatar, M.
    Sarioz, F.
    VALUE IN HEALTH, 2010, 13 (03) : A146 - A147
  • [38] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Aguirre, A.
    Guerrero, E.
    Hernandez, N.
    Coronell, S.
    Argote, A. C.
    Giraldo, C., V
    Ojeda, C.
    VALUE IN HEALTH, 2017, 20 (05) : A211 - A211
  • [39] COST-EFFECTIVENESS OF APREMILAST FOR THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN GREECE
    Solakidi, A.
    Tzanetakos, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2017, 20 (09) : A803 - A803
  • [40] COST-UTILITY OF USTEKINUMAB IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS IN COLOMBIA
    Ojeda, C.
    Hernandez, N.
    Giraldo, C., V
    Argote, A. C.
    Coronell, S.
    Roa, M.
    VALUE IN HEALTH, 2016, 19 (03) : A124 - A124
12345